CISEN(603367)

Search documents
A股异动丨婴童股普涨,免除公办幼儿园学前一年保教费+3周岁以下婴幼儿每孩每年发3600元
Ge Long Hui A P P· 2025-08-06 03:54
Group 1 - The A-share market for baby and child-related stocks experienced a significant increase, with notable gains from companies such as Qide New Materials rising over 8%, Chenxin Pharmaceutical over 7%, and Helen Piano over 5% [1] - The State Council issued an opinion on August 5 to gradually implement free preschool education, starting from the fall semester of 2025, which will exempt public kindergartens from charging care and education fees for children in their final year [1] - A new parenting subsidy system was announced on July 28, which will provide cash subsidies to families with children under three years old, starting from January 1, 2025, with a basic annual subsidy of 3,600 yuan per child [1] Group 2 - Qide New Materials (300995) saw an increase of 8.47% with a total market value of 39.56 billion yuan and a year-to-date increase of 198.59% [2] - Chenxin Pharmaceutical (603367) increased by 7.29%, with a market value of 14.6 billion yuan and a year-to-date increase of 138.23% [2] - Other companies such as Helen Piano (300329) and Hejing Technology (300279) also reported gains of 5.64% and 4.95% respectively, indicating a positive trend in the sector [2]
低开高走,辰欣药业盘中冲上涨停
Bei Jing Shang Bao· 2025-08-06 02:31
北京商报讯(记者 丁宁)8月6日,辰欣药业(603367)低开高走,盘中冲上涨停,截至北京商报记者 发稿,辰欣药业报33.04元/股,涨幅为9.99%。 值得一提的是,8月5日晚间,辰欣药业发布公告称,公司持股5%以上股东韩延振拟合计减持数量不超 过1358.26万股,不超过公司总股本的3%。 东方财富显示,6月27日至8月6日,辰欣药业股价累计涨幅达到138.56%。 ...
最高法披露骗保典型案例;480家药企竞逐第十一批集采 | 健讯Daily
2 1 Shi Ji Jing Ji Bao Dao· 2025-08-06 00:11
Regulatory Changes - The National Health Commission has issued a notice prohibiting medical institutions from using misleading names for outpatient services that imply efficacy, emphasizing the need for clear and accurate naming practices [1] Drug Procurement - The National Medical Insurance Administration announced that 480 pharmaceutical companies are competing in the 11th batch of national drug procurement, with 55 drugs proposed for inclusion, averaging 15 companies per drug, and some drugs having over 40 participating companies [2] Legal Actions Against Fraud - The Supreme People's Court reported a significant increase in the prosecution of medical insurance fraud cases, with 1,156 cases involving 2,299 individuals concluded in 2024, marking a 131.2% year-on-year increase and recovering over 402 million yuan in lost funds [3] Drug Approvals - Innovent Biologics announced that its oral GLP-1R agonist IBI3032 has received FDA approval for clinical trials, with plans to initiate Phase I trials in mid-2025 targeting overweight or obese individuals [4] - Dyne Therapeutics received breakthrough therapy designation from the FDA for its investigational therapy DYNE-251 for Duchenne muscular dystrophy, with data expected by the end of 2025 [5] - Xinhua Pharmaceutical's subsidiary, Xinda Pharmaceutical, has received a drug registration certificate for Finasteride tablets, which are included in the national medical insurance drug list [6][7] Mergers and Acquisitions - Shanghai TuoJing announced the acquisition of 82% of Wuhan Kanglu Biological for 328 million yuan, focusing on advancements in molecular diagnostics [8] Financial Performance - Jiuzhou Pharmaceutical reported a 3.86% increase in revenue to 2.871 billion yuan and a 10.7% increase in net profit to 526 million yuan for the first half of 2025 [10] Strategic Investments - Yabao Pharmaceutical plans to acquire a traditional Chinese medicine project for 22 million yuan, enhancing its R&D pipeline and competitive edge [11] Shareholder Actions - Chenshin Pharmaceutical announced that a major shareholder plans to reduce their stake by up to 3% through market transactions, which is not expected to significantly impact the company's governance or operations [12]
辰欣药业股份有限公司关于持股5%以上股东减持股份计划公告
Zhong Guo Zheng Quan Bao - Zhong Zheng Wang· 2025-08-06 00:06
Group 1 - The major shareholder Han Yanzhen holds 31,977,829 shares of Chenshin Pharmaceutical, accounting for 7.06% of the total share capital before the reduction plan [2] - Han Yanzhen plans to reduce holdings through centralized bidding and block trading, with a total reduction not exceeding 13,582,623 shares, or 3% of the total share capital [2] - The reduction plan will be adjusted if there are changes in the company's capital structure during the reduction period [2][3] Group 2 - The reduction plan is based on the shareholder's personal financial needs and will not significantly impact the company's governance structure or ongoing operations [5] - The implementation of the reduction plan is subject to market conditions, and the timing, quantity, and price of the reduction are uncertain [5] - The reduction plan complies with relevant laws and regulations, and the company will ensure timely disclosure of information during the implementation [7]
【早报】国办发文!免除公办幼儿园学前1年保教费;上交所出手!对上纬新材部分投资者采取暂停账户交易措施
财联社· 2025-08-05 23:10
Macro News - The State Council issued opinions on gradually promoting free preschool education, stating that from the fall semester of 2025, public kindergarten tuition fees for the last year will be waived [1] - Seven departments, including the central bank, jointly issued guidelines to support new industrialization, aiming for a mature financial system for high-end, intelligent, and green manufacturing by 2027 [1] - The National Health Commission and 16 departments released an implementation plan for the "Healthy China Action - Healthy Environment Promotion Action (2025-2030)", with goals to improve drinking water quality and health literacy by 2030 [1] - Regulatory authorities are intensifying efforts to combat market fraud by punishing third-party companies that assist in fraudulent activities for listed companies [1] Industry News - The China Electromechanical Products Import and Export Chamber urged photovoltaic companies to adhere to fair competition principles and control capacity expansion according to global market demand [2] - Trump announced plans to impose drug tariffs, starting small but potentially reaching 250% [2] - The Guizhou Provincial Market Supervision Administration held discussions with travel platform companies to enforce compliance with laws and maintain a fair market environment [2] Company News - Upstream New Materials announced that it may apply for a continuous suspension of trading if its stock price continues to rise [6] - The Shanghai Stock Exchange reported abnormal trading behaviors affecting market order related to Upstream New Materials, leading to account trading suspensions for certain investors [6] Global Market - Major US stock indices closed lower, with the Dow down 0.14%, Nasdaq down 0.65%, and S&P 500 down 0.49% [7] - WTI crude oil futures fell by 1.7% to $65.16 per barrel, while Brent crude oil futures dropped by 1.63% to $67.64 per barrel [8] - COMEX gold futures rose by 0.25% to $3435 per ounce, and silver futures increased by 1.36% to $37.835 per ounce [9] New Stock Information - New stock HanSang Technology (301491) has an issue price of 28.91 with a PE ratio of 14.90, focusing on high-end audio products and solutions [10]
辰欣药业:关于持股5%以上股东减持股份计划公告
Zheng Quan Ri Bao Zhi Sheng· 2025-08-05 14:09
(编辑 李家琪) 证券日报网讯 8月5日晚间,辰欣药业发布公告称,持股5%以上股东韩延振计划减持股份。韩延振拟通 过集中竞价交易方式减持数量不超过4,527,541股,不超过公司总股本的1%;拟通过大宗交易方式减 持数量不超过9,055,082股,不超过公司总股本的2%,合计减持数量不超过13,582,623股,不超过 公司总股本的3%。减持期间为2025年8月29日至2025年11月26日。 ...
8月5日龙虎榜,机构青睐这12股





Zheng Quan Shi Bao Wang· 2025-08-05 12:40
证券时报·数据宝统计显示,8月5日机构专用席位现身26只个股龙虎榜,合计净买入1.18亿元。为连续第 4日净买入。个股来看,净买入12只,净卖出14只。 8月5日沪指上涨0.96%,盘后龙虎榜数据显示,机构现身26只个股龙虎榜,净买入12只,净卖出14只。 深沪股通席位出现在14只个股龙虎榜。 新瀚新材,今日收盘涨停,全天换手率为34.85%,成交额为13.38亿元。因日收盘价涨幅达20.00%上榜 龙虎榜,前五大买卖营业部中有4家机构专用席位,为买一、买四、买五、卖四,合计净买入8480.39万 元。资金流向方面,该股全天资金净流入1.42亿元。 北方长龙,今日收盘上涨14.64%,全天换手率为67.52%,成交额为20.15亿元。因日换手率达67.52%上 榜龙虎榜,前五大买卖营业部中有5家机构专用席位,为买一、买二、买四、卖三、卖五,合计净买入 5200.10万元。资金流向方面,该股全天资金净流出6789.44万元。 从市场表现看,机构净买入个股今日平均上涨11.97%,涨幅强于沪指。东杰智能、新瀚新材等表现强 势,股价以涨停报收。通过对近一个月机构净买入个股进行回测发现,机构净买入个股次日上涨概率为 ...
辰欣药业股东韩延振拟减持不超3%公司股份
Bei Jing Shang Bao· 2025-08-05 11:36
北京商报讯(记者 丁宁)8月5日晚间,辰欣药业(603367)发布公告称,公司持股5%以上股东韩延振 拟通过集中竞价交易方式减持数量不超过452.75万股,不超过公司总股本的1%;拟通过大宗交易方式 减持数量不超过905.51万股,不超过公司总股本的2%,合计减持数量不超过1358.26万股,不超过公司 总股本的3%。 公告显示,韩延振持有辰欣药业无限售流通股份3197.78万股,占辰欣药业总股本的7.06%。 ...
机构今日抛售昂利康等16股,买入东杰智能2.09亿元





3 6 Ke· 2025-08-05 10:49
Summary of Key Points Core Viewpoint - On August 5th, a total of 34 stocks were involved with institutional investors, with 18 showing net buying and 16 showing net selling [1] Institutional Buying - The top three stocks with the highest net buying by institutions were: - Dongjie Intelligent: Net buying amount of 209 million [1] - Xinhang New Materials: Net buying amount of 84.8 million [1] - Gongchuang Turf: Net buying amount of 63.12 million [1] Institutional Selling - The top three stocks with the highest net selling by institutions were: - Anglikang: Net outflow amount of 116 million [1] - Chenxin Pharmaceutical: Net outflow amount of 74.22 million [1] - Shanhe Intelligent: Net outflow amount of 51.28 million [1]
辰欣药业跌6.65%,沪股通龙虎榜上买入7238.31万元,卖出6565.14万元
Zheng Quan Shi Bao Wang· 2025-08-05 10:32
辰欣药业(603367)今日下跌6.65%,全天换手率9.50%,成交额13.19亿元,振幅12.76%。龙虎榜数据显 示,机构净卖出7422.27万元,沪股通净买入673.17万元,营业部席位合计净买入3831.52万元。 上交所公开信息显示,当日该股因日跌幅偏离值达-7.60%上榜,机构专用席位净卖出7422.27万元,沪 股通净买入673.17万元。 证券时报·数据宝统计显示,上榜的前五大买卖营业部合计成交3.70亿元,其中,买入成交额为1.70亿 元,卖出成交额为2.00亿元,合计净卖出2917.58万元。 具体来看,今日上榜的营业部中,共有1家机构专用席位现身,即卖一,合计净卖出7422.27万元,沪股 通为第一大买入营业部及第二大卖出营业部,买入金额为7238.31万元,卖出金额为6565.14万元,合计 净买入673.17万元。 资金流向方面,今日该股主力资金净流出3917.58万元,其中,特大单净流出3740.81万元,大单资金净 流出176.77万元。近5日主力资金净流出5142.53万元。 4月22日公司发布的一季报数据显示,一季度公司共实现营业收入9.20亿元,同比下降19.91%,实现 ...